Triple Negative Breast Cancer Characteristics Based on Basal-like and Non-Basal-like Subtypes

Fifi Akwarini, Trinugroho Heri Fadjari, Bethy Suryawathy Hernowo

Abstract


Objective: To observe triple negative breast cancer (TNBC) characteristics in three hospitals located in Bandung based on basal-like (BL) and non-basal-like (NBL) subtypes.

Methods: This was a cross-sectional study which used descriptive categorical data from medical records and paraffin blocks of TNBC patients treated in Dr. Hasan Sadikin General Hospital, Bandung; Borromeus Hospital; and Santosa Hospital Bandung Central in the period of January 1, 2012–December 31, 2016. The subjects of the study were 57 TNBC patients. The data collected in the study based on medical records were age, tumor size, histopathological images, severity, and immunohistochemical data. The paraffin blocks of the patients based on the completed medicals records were investigated through examinations of immunohistochemichal cytokeratin (CK) 5/6 expressions and epidermal growth factor receptor (EGFR).

Results: Prevalence of TNBC were 82.5% of basal-like subjects and 17.5% of non-basal-like subjects. Among the TNBC subjects, median age of each subtype was 50 years of basal-like subtype and 45 years of non-basal-like subtype. Both subtypes were mostly found in the subjects who aged >40 years. Higher histopathological grade was discovered in both subtypes. The therapy mostly carried out to the subjects was adjuvant chemotherapy. Majority of basal-like subtype subjects were still alive and had longer survival rate and lower incidences of deaths when compared to the non-basal-like subtype.

Conclusion: In TNBC, the basal-like subjects showed greater median age, lower severity stage, and longer survival rate than the non-basal-like subjects. There was no histopathology grade between both subtypes. 

Keywords: Basal-like and non-basal-like subtypes, breast cancer, characteristics, triple negative

 

DOI: 10.15850/ijihs.v7n1.1570


Keywords


Basal-like and non-basal-like subtypes, breast cancer, characteristics, triple negative

Full Text:

PDF

References


Kementerian Kesehatan Republik Indonesia. Kanker payudara. Jakarta: Komite Penanggunalangan Kanker Nasional; 2017.

Choccalingan C, Rao L, Rao S. Clinico-pathological characteristic of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expresion at a rural tertary hospital in India. Breast Cancer (Auckl). 2012;6(1):21–9.

Pillai SKK, Tay A, Nair S, Leong CO. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol. 2012;12(1):1–18.

Toft DJ, Cryns VL. Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011;25(2):199–211.

Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple negative breast cancer. J Cklin Oncol. 2012;30(15):1879–87.

Thike AA, Cheok PY, Jara Lazaro, Tan B, Tan P, and Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23(1):122–33.

Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res [serial on the internet]. 2015 Mar [cited 2017 Jun 12];17(43):[about 16p.]. Available from: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0550-y.

Prat A., Adama B, Chang MCU, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123–33.

Sharma P. Biology and management of patients with triple negative breast cancer. Oncologist. 2016;21(9):1050–62.

Seal MD, Chia SK. What is the difference between triple negative and basal breast cancer? Cancer J .2010;16(1):12–6.

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, et al. Comparing of IRS and HER2 as immunohistochemicl scoring schemes in gastropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187–94.

American Cancer Society. Breast cancer facts & figures 2011–2012. Atlanta: American Cancer Society Inc.; 2011.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumor: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Review. Nat Clin Pract Oncol. 2008;5(3):149–59.




DOI: https://doi.org/10.15850/ijihs.v7n1.1570



This journal indexed by:

              

  

Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License



View My Stats